RegenxBio raises $201.8M follow-on
RegenxBio Inc. (NASDAQ:RGNX) raised $201.8 million through the sale of 3.1 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James. The number includes a 405,000 share overallotment raised on Aug. 14.
The company disclosed a treatment-related serious adverse event (SAE) in which a patient was hospitalized with transient, asymptomatic elevated transaminases in a Phase I/II trial of RGX-501 to treat homozygous familial hypercholesterolemia (HoFH). The company previously reported a treatment-related SAE of mild transitory immune system activation accompanied by hypotension and elevated transaminases in the trial (see “RegnexBio Discloses Second Serious AE for Hypercholesterolemia Gene Therapy”)...
BCIQ Company Profiles